Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Abstract Background Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash...

Full description

Bibliographic Details
Main Authors: Ashley M. Hopkins, Akash D. Rathod, Andrew Rowland, Ganessan Kichenadasse, Michael J. Sorich
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cancer
Subjects:
BRAF inhibitor
Vemurafenib
Severe rash
Toxicity
Predictors
Risk factor
Online Access:http://link.springer.com/article/10.1186/s12885-020-6659-0

Internet

http://link.springer.com/article/10.1186/s12885-020-6659-0

Similar Items